Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Shionogi moved Sept. 1 to establish a sales presence in the U.S. through the acquisition of Atlanta-based Sciele Pharma. Boards of both firms approved the $1.42 billion purchase, for $31 per share, prior to the announcement
You may also be interested in...
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change